Review



ev enriched secretome preparations  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Miltenyi Biotec ev enriched secretome preparations
    GMP‐manufacturing process for an EV‐enriched <t>secretome</t> from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.
    Ev Enriched Secretome Preparations, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 109 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ev+enriched+secretome+preparations/MACSPlex+EV+Kit+IO%2C+human/pmc12365392-126-12-19
    Average 97 stars, based on 109 article reviews
    ev enriched secretome preparations - by Bioz Stars, 2026-09
    97/100 stars

    Images

    1) Product Images from "GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial"

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial

    Journal: Journal of Extracellular Vesicles

    doi: 10.1002/jev2.70145

    GMP‐manufacturing process for an EV‐enriched secretome from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.
    Figure Legend Snippet: GMP‐manufacturing process for an EV‐enriched secretome from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.

    Techniques Used:

    FIGURE 4 Characterisation of the EV‐enriched secretome composition. (a) Total read distribution (%) of different small RNA biotypes in the final product. Small RNA sequencing results were mapped to the human genome to determine the percentage of each RNA biotype. Sequences corresponding to all micro‐RNA (miRNA) reads, ribosomal RNA (rRNA), non‐coding RNA (ncRNA), remaining reads, mature transfer RNA (mature tRNA), small nucleolar RNA (snoRNA), mature micro‐RNA (mature miRNA), primary transfer RNA (primary tRNA) and hairpin micro‐RNA (hairpin miRNA) were identified. Note that the sequencing method is not optimal for identifying long reads, including mRNA. (b) Transcriptomics. The graph represents the top 20 most abundant miRNA identified in the final product, given as a percentage of expression (%). (c) Protein quantity. The total quantity of protein (mg) was measured in spent media, CCM after clarification, retentate and final product, using a BC Assay Kit. (d) Proteomics results. The most abundant proteins identified in the final product and their relative abundance (mass percentages) are shown. COL6A1, collagen alpha‐1(VI) chain; ALDOA, fructose‐bisphosphate aldolase A; FSCN1, Fascin; C5, complement C5 ; FLNC, filamin‐C; COL5A1, collagen alpha‐1(V) chain; IGFBP7, insulin‐like growth factor‐binding protein 7; FLNB, filamin‐B; SPTAN1, spectrin alpha chain, non‐erythrocytic 1; ENO1, alpha‐enolase; LAMB1, laminin subunit beta‐1; MYH9, myosin‐9; FBN2, fibrillin‐2; DAG1, dystroglycan; ACTN4, alpha‐actinin‐4; VIM, vimentin; LAMA1, laminin subunit alpha‐1; A2M, alpha‐2‐macroglobulin; LAMA5, laminin subunit alpha‐5; HAPLN1, hyaluronan and proteoglycan link protein 1; COL2A1, collagen alpha‐1(II) chain; PROS1, vitamin K‐dependent protein S; FSTL1, follistatin‐related protein 1; FBLN2, fibulin‐2; AGRN, agrin; VCAN, versican core protein; FLNA, filamin‐A; MASP1, mannan‐binding lectin serine protease 1; CDH2, cadherin‐2; SPARC, SPARC; HSPG2, basement membrane‐specific heparan sulphate proteoglycan core protein; ALB, albumin; FN1, fibronectin. (e) Gene ontology enrichment analysis in terms of biological process, analysed using String Prot.
    Figure Legend Snippet: FIGURE 4 Characterisation of the EV‐enriched secretome composition. (a) Total read distribution (%) of different small RNA biotypes in the final product. Small RNA sequencing results were mapped to the human genome to determine the percentage of each RNA biotype. Sequences corresponding to all micro‐RNA (miRNA) reads, ribosomal RNA (rRNA), non‐coding RNA (ncRNA), remaining reads, mature transfer RNA (mature tRNA), small nucleolar RNA (snoRNA), mature micro‐RNA (mature miRNA), primary transfer RNA (primary tRNA) and hairpin micro‐RNA (hairpin miRNA) were identified. Note that the sequencing method is not optimal for identifying long reads, including mRNA. (b) Transcriptomics. The graph represents the top 20 most abundant miRNA identified in the final product, given as a percentage of expression (%). (c) Protein quantity. The total quantity of protein (mg) was measured in spent media, CCM after clarification, retentate and final product, using a BC Assay Kit. (d) Proteomics results. The most abundant proteins identified in the final product and their relative abundance (mass percentages) are shown. COL6A1, collagen alpha‐1(VI) chain; ALDOA, fructose‐bisphosphate aldolase A; FSCN1, Fascin; C5, complement C5 ; FLNC, filamin‐C; COL5A1, collagen alpha‐1(V) chain; IGFBP7, insulin‐like growth factor‐binding protein 7; FLNB, filamin‐B; SPTAN1, spectrin alpha chain, non‐erythrocytic 1; ENO1, alpha‐enolase; LAMB1, laminin subunit beta‐1; MYH9, myosin‐9; FBN2, fibrillin‐2; DAG1, dystroglycan; ACTN4, alpha‐actinin‐4; VIM, vimentin; LAMA1, laminin subunit alpha‐1; A2M, alpha‐2‐macroglobulin; LAMA5, laminin subunit alpha‐5; HAPLN1, hyaluronan and proteoglycan link protein 1; COL2A1, collagen alpha‐1(II) chain; PROS1, vitamin K‐dependent protein S; FSTL1, follistatin‐related protein 1; FBLN2, fibulin‐2; AGRN, agrin; VCAN, versican core protein; FLNA, filamin‐A; MASP1, mannan‐binding lectin serine protease 1; CDH2, cadherin‐2; SPARC, SPARC; HSPG2, basement membrane‐specific heparan sulphate proteoglycan core protein; ALB, albumin; FN1, fibronectin. (e) Gene ontology enrichment analysis in terms of biological process, analysed using String Prot.

    Techniques Used: RNA Sequencing, Sequencing, Expressing, Clarification Assay, Binding Assay, Membrane

    Summary of the components and biological effects of the EV‐enriched secretome final product. (a) Some of the protein and molecular components identified in the final product. Image created with BioRender.com . (b) Summary of cell surface markers identified by the MACSPlex Exosome kit in the final product, which their known roles in biological processes. (c) Functional effects of the final product. Image created with BioRender.com .
    Figure Legend Snippet: Summary of the components and biological effects of the EV‐enriched secretome final product. (a) Some of the protein and molecular components identified in the final product. Image created with BioRender.com . (b) Summary of cell surface markers identified by the MACSPlex Exosome kit in the final product, which their known roles in biological processes. (c) Functional effects of the final product. Image created with BioRender.com .

    Techniques Used: Functional Assay



    Similar Products

    ev enriched secretome preparations  (Miltenyi Biotec)
    97
    Miltenyi Biotec ev enriched secretome preparations
    GMP‐manufacturing process for an EV‐enriched <t>secretome</t> from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.
    Ev Enriched Secretome Preparations, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ev+enriched+secretome+preparations/MACSPlex+EV+Kit+IO%2C+human/pmc12365392-126-12-19
    Average 97 stars, based on 1 article reviews
    ev enriched secretome preparations - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    GMP‐manufacturing process for an EV‐enriched secretome from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.

    Journal: Journal of Extracellular Vesicles

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial

    doi: 10.1002/jev2.70145

    Figure Lengend Snippet: GMP‐manufacturing process for an EV‐enriched secretome from CPC. (a) Schematic representation of the three main steps of the GMP‐manufacturing of the EV‐enriched secretome final product. (b) Overview of the QC strategy for the characterisation of CPC during the manufacturing process (in‐process monitoring) and of the final product. M/F, Male/Female. Image created with BioRender.com.

    Article Snippet: Particle identity : To characterise the surface markers of particles in the EV‐enriched secretome preparations, the MACSPlex Exosome Kit (Miltenyi Biotec, #130‐108‐813) was used following the manufacturer's instructions.

    Techniques:

    FIGURE 4 Characterisation of the EV‐enriched secretome composition. (a) Total read distribution (%) of different small RNA biotypes in the final product. Small RNA sequencing results were mapped to the human genome to determine the percentage of each RNA biotype. Sequences corresponding to all micro‐RNA (miRNA) reads, ribosomal RNA (rRNA), non‐coding RNA (ncRNA), remaining reads, mature transfer RNA (mature tRNA), small nucleolar RNA (snoRNA), mature micro‐RNA (mature miRNA), primary transfer RNA (primary tRNA) and hairpin micro‐RNA (hairpin miRNA) were identified. Note that the sequencing method is not optimal for identifying long reads, including mRNA. (b) Transcriptomics. The graph represents the top 20 most abundant miRNA identified in the final product, given as a percentage of expression (%). (c) Protein quantity. The total quantity of protein (mg) was measured in spent media, CCM after clarification, retentate and final product, using a BC Assay Kit. (d) Proteomics results. The most abundant proteins identified in the final product and their relative abundance (mass percentages) are shown. COL6A1, collagen alpha‐1(VI) chain; ALDOA, fructose‐bisphosphate aldolase A; FSCN1, Fascin; C5, complement C5 ; FLNC, filamin‐C; COL5A1, collagen alpha‐1(V) chain; IGFBP7, insulin‐like growth factor‐binding protein 7; FLNB, filamin‐B; SPTAN1, spectrin alpha chain, non‐erythrocytic 1; ENO1, alpha‐enolase; LAMB1, laminin subunit beta‐1; MYH9, myosin‐9; FBN2, fibrillin‐2; DAG1, dystroglycan; ACTN4, alpha‐actinin‐4; VIM, vimentin; LAMA1, laminin subunit alpha‐1; A2M, alpha‐2‐macroglobulin; LAMA5, laminin subunit alpha‐5; HAPLN1, hyaluronan and proteoglycan link protein 1; COL2A1, collagen alpha‐1(II) chain; PROS1, vitamin K‐dependent protein S; FSTL1, follistatin‐related protein 1; FBLN2, fibulin‐2; AGRN, agrin; VCAN, versican core protein; FLNA, filamin‐A; MASP1, mannan‐binding lectin serine protease 1; CDH2, cadherin‐2; SPARC, SPARC; HSPG2, basement membrane‐specific heparan sulphate proteoglycan core protein; ALB, albumin; FN1, fibronectin. (e) Gene ontology enrichment analysis in terms of biological process, analysed using String Prot.

    Journal: Journal of Extracellular Vesicles

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial

    doi: 10.1002/jev2.70145

    Figure Lengend Snippet: FIGURE 4 Characterisation of the EV‐enriched secretome composition. (a) Total read distribution (%) of different small RNA biotypes in the final product. Small RNA sequencing results were mapped to the human genome to determine the percentage of each RNA biotype. Sequences corresponding to all micro‐RNA (miRNA) reads, ribosomal RNA (rRNA), non‐coding RNA (ncRNA), remaining reads, mature transfer RNA (mature tRNA), small nucleolar RNA (snoRNA), mature micro‐RNA (mature miRNA), primary transfer RNA (primary tRNA) and hairpin micro‐RNA (hairpin miRNA) were identified. Note that the sequencing method is not optimal for identifying long reads, including mRNA. (b) Transcriptomics. The graph represents the top 20 most abundant miRNA identified in the final product, given as a percentage of expression (%). (c) Protein quantity. The total quantity of protein (mg) was measured in spent media, CCM after clarification, retentate and final product, using a BC Assay Kit. (d) Proteomics results. The most abundant proteins identified in the final product and their relative abundance (mass percentages) are shown. COL6A1, collagen alpha‐1(VI) chain; ALDOA, fructose‐bisphosphate aldolase A; FSCN1, Fascin; C5, complement C5 ; FLNC, filamin‐C; COL5A1, collagen alpha‐1(V) chain; IGFBP7, insulin‐like growth factor‐binding protein 7; FLNB, filamin‐B; SPTAN1, spectrin alpha chain, non‐erythrocytic 1; ENO1, alpha‐enolase; LAMB1, laminin subunit beta‐1; MYH9, myosin‐9; FBN2, fibrillin‐2; DAG1, dystroglycan; ACTN4, alpha‐actinin‐4; VIM, vimentin; LAMA1, laminin subunit alpha‐1; A2M, alpha‐2‐macroglobulin; LAMA5, laminin subunit alpha‐5; HAPLN1, hyaluronan and proteoglycan link protein 1; COL2A1, collagen alpha‐1(II) chain; PROS1, vitamin K‐dependent protein S; FSTL1, follistatin‐related protein 1; FBLN2, fibulin‐2; AGRN, agrin; VCAN, versican core protein; FLNA, filamin‐A; MASP1, mannan‐binding lectin serine protease 1; CDH2, cadherin‐2; SPARC, SPARC; HSPG2, basement membrane‐specific heparan sulphate proteoglycan core protein; ALB, albumin; FN1, fibronectin. (e) Gene ontology enrichment analysis in terms of biological process, analysed using String Prot.

    Article Snippet: Particle identity : To characterise the surface markers of particles in the EV‐enriched secretome preparations, the MACSPlex Exosome Kit (Miltenyi Biotec, #130‐108‐813) was used following the manufacturer's instructions.

    Techniques: RNA Sequencing, Sequencing, Expressing, Clarification Assay, Binding Assay, Membrane

    Summary of the components and biological effects of the EV‐enriched secretome final product. (a) Some of the protein and molecular components identified in the final product. Image created with BioRender.com . (b) Summary of cell surface markers identified by the MACSPlex Exosome kit in the final product, which their known roles in biological processes. (c) Functional effects of the final product. Image created with BioRender.com .

    Journal: Journal of Extracellular Vesicles

    Article Title: GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial

    doi: 10.1002/jev2.70145

    Figure Lengend Snippet: Summary of the components and biological effects of the EV‐enriched secretome final product. (a) Some of the protein and molecular components identified in the final product. Image created with BioRender.com . (b) Summary of cell surface markers identified by the MACSPlex Exosome kit in the final product, which their known roles in biological processes. (c) Functional effects of the final product. Image created with BioRender.com .

    Article Snippet: Particle identity : To characterise the surface markers of particles in the EV‐enriched secretome preparations, the MACSPlex Exosome Kit (Miltenyi Biotec, #130‐108‐813) was used following the manufacturer's instructions.

    Techniques: Functional Assay